In the vaccine scene on the global level, Bharat Biotech is one name that is doing a super good job, but not a lot of people truly know about it right here in India. So, let’s briefly talk about this amazing company, more specifically, let’s talk about things like Bharat Biotech Net Worth, Owner, CEO, Head Office, etc.
| Company Name | Bharat Biotech International Limited |
| Establishment Year | 1996 |
| Head Office | Hyderabad |
| Owner/Founder | Dr. Krishna M. Ella and Mrs. Suchitra K. Ella |
| CEO Name | Executive Chairman: Dr. Krishna M. Ella, Managing Director: Mrs. Suchitra K. Ella |
| Industry | Biotechnology, Vaccines, and Bio-therapeutics |
| Net Worth/Market Cap | Not publicly available |
Company Overview
Not a lot of people know this, but Bharat Biotech is a well-known vaccine manufacturer, which is mainly based in India. It was established in 1996 by Dr. Krishna Ella and his better half, Mrs. Suchitra Ella, in Hyderabad. Dr. Ella, after studying at the University of Wisconsin in the U.S., came back to India with only one objective, you know, to produce top-notch vaccines for the Third World countries, but at a price that they can afford. That’s how this company made it BIG. Currently, though, their head office is in Hyderabad.
Financial Performance
Bharat Biotech is performing magnificently. Like, for example, the firm’s reported revenues for 2024 were close to ₹1,323 crore, and the following year, the figures increased to about ₹1,463 crore; that pretty much means the growth has been quite steady. The profit margin situation also got better as the company’s profit margin increased from 8.8% in 2024 to 28.2% in 2025, which is an obvious indication of better management of the operations and increased efficiency.
Recent Developments and Future Plans
In the first place, Big Pharma has been able to distribute more than 9 billion vaccine doses around the globe, and it holds more than 220 patents. Recently, the company has been venturing into different sectors of the healthcare industry. In the year 2025, the company made an announcement about its cell and gene therapy program. Biologics and genetic engineering are the primary themes of the therapies, and they sound like a very big turn for the company, which still seems to be consistent with its modernization philosophy.